China (Mainland)
Premiumsupplier
Lorlatinib (PF-06463922） CAS NO.1454846-35-5
- Min.Order: 0 Metric Ton
- Payment Terms: L/C,T/T,MoneyGram,Other
- Product Details
Keywords
- Lorlatinib
- PF-06463922
- 1454846-35-5
Quick Details
- ProName: Lorlatinib (PF-06463922）
- CasNo: 1454846-35-5
- Molecular Formula: C21H19FN6O2
- Appearance: Off-white to white solid powder
- Application: Anaplastic lymphoma kinase (ALK) is a ...
- DeliveryTime: Within 3-7 days after receipt of your ...
- PackAge: As customer request
- Port: Qingdao\Shanghai,China
- ProductionCapacity: 100 Kilogram/Week
- Purity: 98+%
- Storage: Store in a cool,dry place and keep awa...
- Transportation: By Sea/Air/Courier
- LimitNum: 0 Metric Ton
- Moisture Content: 0.2%max
- Impurity: 0.1%max
- Appearance: N/A
- Boiling point: 675.0±55.0 °C(Predicted)
- Density: 1.42±0.1 g/cm3(Predicted)
Superiority
Details
Lorlatinib(PF-06463922,1454846-35-5)
[Product Name]:PF-06463922
[CAS]:1454846-35-5
[MF]:C21H19FN6O2
[MW]:406.4129632
[EINECS]:813-704-5
[Assay]:98%min
[Appearance]:white Powder
[Stock]: less than 500g
[Customer Synthesis]: Avilable
Biological Activity of Lorlatinib(PF-06463922,1454846-35-5)
Description High affinity and selective ALK and ROS1 inhibitor (Ki values are <0.02, <0.07 and 0.7 nM for ROS1, wild-type ALK and ALK-L1196M, respectively). Exhibits >100-fold selectivity for ROS1 over a panel of 204 other kinases. Inhibits proliferation of BaF3 cells containing crizotinib-resistant ROS1 mutation in vitro. Inhibits tumor growth in relevant mouse models. Orally available and brain penetrant.
PF-06463922 Usage And Synthesis
| Uses | Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that promotes cell proliferation and blocks apoptosis. PF-06463922 is an ATP-competitive, selective inhibitor of ALK (Ki = < 0.07 nM) and c-Ros oncogene 1 (ROS1, Ki = 0.7 nM). It has strong activity against all known ALK and ROS1 mutants identified in patients, including the EML4-L1196M mutant of ALK (Ki = < 0.02 nM). PF-06463922 is orally available, displaying inhibition of ALK phosphorylation and antitumor efficacy in a xenograft model expressing EML4-L1196M ALK. It demonstrates efficient blood-brain barrier penetration, produces brain tumor regression in mice harboring EML4-ALK tumors, and increases overall survival.[Cayman Chemical] |
| Enzyme inhibitor | This potent, dual ALK/ROS1 inhibitor (FW = 406.41 g/mol; CAS 1454846- 35-5), also named (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro- 2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3- h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, targets the protooncogene tyrosine-protein kinase ROS1 (Ki < 0.02 nM) as well as wild-type anaplastic lymphoma kinase ALKWT (Ki < 0.07 nM) and its Leu-to-Met mutant ALKL1196M (Ki of = 0.7 nM). PF-06463922 significantly inhibits cell proliferation and induces cell apoptosis in the HCC78 human NSCLC cells harboring SLC34A2-ROS1 fusions and the BaF3-CD74-ROS1 cells expressing human CD74-ROS1 |
